Journal
ADVANCED MATERIALS
Volume 30, Issue 22, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/adma.201707113
Keywords
drug delivery; immunomodulation; nanomedicine; nucleic acid delivery
Categories
Funding
- National Cancer Institute of the National Institutes of Health [U54CA199091]
- Vannevar Bush Faculty Fellowship program - Basic Research Office of the Assistant Secretary of Defense for Research and Engineering
- Office of Naval Research [N00014-15-1-0043]
- American Cancer Society [RSG-14-098-01-CCE]
- Netherlands Organization for Scientific Research [680-50-1512]
- Chicago Cancer Baseball Charities at the Lurie Cancer Center of Northwestern University
- NATIONAL CANCER INSTITUTE [U54CA199091] Funding Source: NIH RePORTER
Ask authors/readers for more resources
A new class of polymer spherical nucleic acid (SNA) conjugates comprised of poly(lactic-co-glycolic acid) (PLGA) nanoparticle (NP) cores is reported. The nucleic acid shell that defines the PLGA-SNA exhibits a half-life of more than 2 h in fetal bovine serum. Importantly, the PLGA-SNAs can be utilized to encapsulate a hydrophobic model drug, coumarin 6, which can then be released in a polymer composition-dependent tunable manner, while the dissociation rate of the nucleic acid shell remains relatively constant, regardless of core composition. Like prototypical gold NP conjugate SNAs, PLGA-SNAs freely enter Raw-Blue cells and can be used to activate toll-like receptor 9 in a sequence- and dose-dependent manner. Taken together, the data show that this novel nanoconstruct provides a means for controlling the release kinetics of encapsulated cargos in the context of the SNA platform, which may be useful for developing combination therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available